{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:15:23Z","timestamp":1791818123803,"version":"4.3.4"},"reference-count":69,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T00:00:00Z","timestamp":1694476800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of China","award":["32101130"],"award-info":[{"award-number":["32101130"]}]},{"name":"National Natural Science Foundation of China","award":["21721002"],"award-info":[{"award-number":["21721002"]}]},{"name":"National Natural Science Foundation of China","award":["31971295"],"award-info":[{"award-number":["31971295"]}]},{"name":"National Natural Science Foundation of China","award":["XDB36000000"],"award-info":[{"award-number":["XDB36000000"]}]},{"name":"National Natural Science Foundation of China","award":["2021ZD0202200"],"award-info":[{"award-number":["2021ZD0202200"]}]},{"name":"National Natural Science Foundation of China","award":["2021ZD0202201"],"award-info":[{"award-number":["2021ZD0202201"]}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["32101130"],"award-info":[{"award-number":["32101130"]}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["21721002"],"award-info":[{"award-number":["21721002"]}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["31971295"],"award-info":[{"award-number":["31971295"]}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["XDB36000000"],"award-info":[{"award-number":["XDB36000000"]}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["2021ZD0202200"],"award-info":[{"award-number":["2021ZD0202200"]}]},{"name":"Strategic Priority Research Program of the Chinese Academy of Sciences","award":["2021ZD0202201"],"award-info":[{"award-number":["2021ZD0202201"]}]},{"name":"National Science and Technology Innovation 2030 Major Program","award":["32101130"],"award-info":[{"award-number":["32101130"]}]},{"name":"National Science and Technology Innovation 2030 Major Program","award":["21721002"],"award-info":[{"award-number":["21721002"]}]},{"name":"National Science and Technology Innovation 2030 Major Program","award":["31971295"],"award-info":[{"award-number":["31971295"]}]},{"name":"National Science and Technology Innovation 2030 Major Program","award":["XDB36000000"],"award-info":[{"award-number":["XDB36000000"]}]},{"name":"National Science and Technology Innovation 2030 Major Program","award":["2021ZD0202200"],"award-info":[{"award-number":["2021ZD0202200"]}]},{"name":"National Science and Technology Innovation 2030 Major Program","award":["2021ZD0202201"],"award-info":[{"award-number":["2021ZD0202201"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Chronic myeloid leukemia (CML) is recognized as a classic clonal myeloproliferative disorder. Given the limited treatment options for CML patients in the accelerated phase (AP) and blast phase (BP), there is an evident need to develop new therapeutic strategies. This has the potential to improve outcomes for individuals in the advanced stages of CML. A promising therapeutic target is Wilms\u2019 tumor 1 (WT1), which is highly expressed in BP-CML cells and plays a crucial role in CML progression. In this study, a chemically synthesized nucleus-targeting WT1 antagonistic peptide termed WIP2W was identified. The therapeutic implications of both the peptide and its micellar formulation, M\u2014WIP2W, were evaluated in WT1+ BP-CML cell lines and in mice. The findings indicate that WIP2W can bind specifically to the WT1 protein, inducing cell cycle arrest and notable cytotoxicity in WT1+ BP-CML cells. Moreover, subcutaneous injections of M\u2014WIP2W were observed to significantly enhance intra-tumoral accumulation and to effectively inhibit tumor growth. Thus, WIP2W stands out as a potent and selective WT1 inhibitor, and the M\u2014WIP2W nanoformulation appears promising for the therapeutic treatment of refractory CML as well as other WT1-overexpressing malignant cancers.<\/jats:p>","DOI":"10.3390\/pharmaceutics15092305","type":"journal-article","created":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T04:38:48Z","timestamp":1694493528000},"page":"2305","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Nucleus-Targeting WT1 Antagonistic Peptide Encapsulated in Polymeric Nanomicelles Combats Refractory Chronic Myeloid Leukemia"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4782-6240","authenticated-orcid":false,"given":"Mengting","family":"Chen","sequence":"first","affiliation":[{"name":"CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaocui","family":"Fang","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Du","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Meng","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Liu","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingpeng","family":"Liu","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"},{"name":"Department of Chemistry, Tsinghua University, Beijing 100084, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4318-7672","authenticated-orcid":false,"given":"Yanlian","family":"Yang","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Wang","sequence":"additional","affiliation":[{"name":"CAS Key Laboratory of Biological Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing 100190, China"},{"name":"University of Chinese Academy of Sciences, Beijing 100049, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1182\/blood.V82.6.1838.1838","article-title":"Role of p21 RAS in p210 bcr-abl transformation of murine myeloid cells","volume":"82","author":"Mandanas","year":"1993","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"11746","DOI":"10.1073\/pnas.92.25.11746","article-title":"The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation","volume":"92","author":"Raitano","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","article-title":"Dominant negative MYC blocks transformation by ABL oncogenes","volume":"70","author":"Sawyers","year":"1992","journal-title":"Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100825","DOI":"10.1016\/j.blre.2021.100825","article-title":"Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions","volume":"49","author":"Osman","year":"2021","journal-title":"Blood Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nrd773","article-title":"Protein kinases\u2014The major drug targets of the twenty-first century?","volume":"1","author":"Cohen","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s40265-014-0216-6","article-title":"Ponatinib: A review of its use in adults with chronic myeloid leukaemia or Philadelphia chromosome-positive acute lymphoblastic leukaemia","volume":"74","author":"Hoy","year":"2014","journal-title":"Drugs"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4987","DOI":"10.2147\/CMAR.S314343","article-title":"Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients","volume":"13","author":"Wang","year":"2021","journal-title":"Cancer Manag. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s12185-019-02801-z","article-title":"Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: The D-NewS Study of the Kanto CML Study Group","volume":"111","author":"Yamaguchi","year":"2020","journal-title":"Int. J. Hematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.leu.2404227","article-title":"Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis","volume":"20","author":"Zheng","year":"2006","journal-title":"Leukemia"},{"key":"ref_14","first-page":"547","article-title":"Blastic phase of chronic myelogenous leukemia","volume":"3","author":"Morris","year":"2005","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/bjh.18370","article-title":"Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity","volume":"199","author":"Copland","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/ajh.21123","article-title":"WT1 protein expression in childhood acute leukemia","volume":"83","author":"Kerst","year":"2008","journal-title":"Am. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bcmd.2012.04.001","article-title":"Expression of four major WT1 splicing variants in acute and chronic myeloid leukemia patients analyzed by newly developed four real-time RT PCRs","volume":"49","author":"Schwarz","year":"2012","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1476-4598-12-3","article-title":"The Wilms\u2019 tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells","volume":"12","author":"Brett","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1038\/srep08924","article-title":"Wilms\u2019 tumor 1 (WT1) expression and prognosis in solid cancer patients: A systematic review and meta-analysis","volume":"5","author":"Qi","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"43634","DOI":"10.1074\/jbc.M111.310128","article-title":"WT1 protein directly regulates expression of vascular endothelial growth factor and is a mediator of tumor response to hypoxia","volume":"286","author":"McCarty","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/sj.leu.2402988","article-title":"WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: Therapeutic potential of WT1 targeted therapies","volume":"17","author":"Rosenfeld","year":"2003","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1182\/blood.V84.9.3071.3071","article-title":"WT1 as a New Prognostic Factor and a New Marker for the Detection of Minimal Residual Disease in Acute Leukemia","volume":"84","author":"Inoue","year":"1994","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.leukres.2004.08.003","article-title":"Quantitative RT-PCR of Wilms tumor gene transcripts (WT1) for the molecular monitoring of patients with accelerated phase bcr\/abl + CML","volume":"29","author":"Na","year":"2005","journal-title":"Leuk. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/med.21886","article-title":"Targeting key proteins involved intranscriptional regulation for cancer therapy: Current strategies and future prospective","volume":"42","author":"Pei","year":"2022","journal-title":"Med. Res. Rev."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"114904","DOI":"10.1016\/j.addr.2023.114904","article-title":"Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems","volume":"199","author":"Shi","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2217\/nnm-2020-0220","article-title":"Peptide-based combination nanoformulations for cancer therapy","volume":"15","author":"Mehrotra","year":"2020","journal-title":"Nanomedicine"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"110194","DOI":"10.1016\/j.cbi.2022.110194","article-title":"Anticancer peptides mechanisms, simple and complex","volume":"368","author":"Norouzi","year":"2022","journal-title":"Chem. Biol. Interact."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.fob.2014.01.007","article-title":"A novel cell-penetrating peptide derived from WT1 enhances p53 activity, induces cell senescence and displays antimelanoma activity in xeno- and syngeneic systems","volume":"4","author":"Massaoka","year":"2014","journal-title":"FEBS Open Bio"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"16228","DOI":"10.1038\/srep16228","article-title":"Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4\/CXCL12 axis","volume":"5","author":"Li","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s13045-021-01206-y","article-title":"A novel CD123-targeted therapeutic peptide loaded by micellar delivery system combats refractory acute myeloid leukemia","volume":"14","author":"Xu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e2001890","DOI":"10.1002\/smll.202001890","article-title":"Synthetic CXCR4 Antagonistic Peptide Assembling with Nanoscaled Micelles Combat Acute Myeloid Leukemia","volume":"16","author":"Meng","year":"2020","journal-title":"Small"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"121894","DOI":"10.1016\/j.ijpharm.2022.121894","article-title":"A nucleus-targeting peptide antagonist towards EZH2 displays therapeutic efficacy for lung cancer","volume":"622","author":"Jiang","year":"2022","journal-title":"Int. J. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s11095-023-03486-0","article-title":"Strategies to improve the physicochemical properties of peptide-based drugs","volume":"40","author":"Lee","year":"2023","journal-title":"Pharm. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: Recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nature Nanotechnol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hanafy, N.A.N., El-Kemary, M., and Leporatti, S. (2018). Micelles Structure Development as a Strategy to Improve Smart Cancer Therapy. Cancers, 10.","DOI":"10.3390\/cancers10070238"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","article-title":"Liposomal drug delivery systems: From concept to clinical applications","volume":"65","author":"Allen","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Wang, S., Chen, Y., Guo, J., and Huang, Q. (2023). Liposomes for Tumor Targeted Therapy: A Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032643"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11095-006-9132-0","article-title":"Micellar Nanocarriers: Pharmaceutical Perspectives","volume":"24","author":"Torchilin","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"20220517","DOI":"10.1515\/ntrev-2022-0517","article-title":"Solid lipid nanoparticles for targeted natural and synthetic drugs delivery in high-incidence cancers, and other diseases: Roles of preparation methods, lipid composition, transitional stability, and release profiles in nanocarriers\u2019 development","volume":"12","author":"Mohammed","year":"2023","journal-title":"Nanotechnol. Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"120183","DOI":"10.1016\/j.ijpharm.2020.120183","article-title":"Enhanced lymphatic delivery of nanomicelles encapsulating CXCR4-recognizing peptide and doxorubicin for the treatment of breast cancer","volume":"594","author":"Fang","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1080\/17425247.2022.2034784","article-title":"An update on cell-penetrating peptides with intracellular organelle targeting","volume":"19","author":"Cerrato","year":"2022","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Bottens, R.A., and Yamada, T. (2022). Cell-Penetrating Peptides (CPPs) as Therapeutic and Diagnostic Agents for Cancer. Cancers, 14.","DOI":"10.3390\/cancers14225546"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"110440","DOI":"10.1016\/j.colsurfb.2019.110440","article-title":"Nuclear-targeted p53 and DOX co-delivery of chitosan derivatives for cancer therapy in vitro and in vivo","volume":"183","author":"Lin","year":"2019","journal-title":"Colloids Surf. B"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"104475","DOI":"10.1016\/j.jddst.2023.104475","article-title":"Penetrating peptides: Applications in drug delivery","volume":"84","author":"Xu","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1038\/oncsis.2016.14","article-title":"A HSP60-targeting peptide for cell apoptosis imaging","volume":"5","author":"Yang","year":"2016","journal-title":"Oncogenesis"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s11095-009-0029-6","article-title":"Pegylated phospholipids-based self-assembly with water-soluble drugs","volume":"27","author":"Wang","year":"2010","journal-title":"Pharm. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/ijc.2910180405","article-title":"Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia","volume":"18","author":"Klein","year":"1976","journal-title":"Int. J. Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.3892\/or.2014.3529","article-title":"Role of the Wilms\u2019 tumor 1 gene in the aberrant biological behavior of leukemic cells and the related mechanisms","volume":"32","author":"Li","year":"2014","journal-title":"Oncol. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jconrel.2016.03.020","article-title":"Cell-penetrating peptides as noninvasive transmembrane vectors for the development of novel multifunctional drug-delivery systems","volume":"229","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/0092-8674(88)90263-2","article-title":"Cellular uptake of the tat protein from human immunodeficiency virus","volume":"55","author":"Frankel","year":"1988","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1080\/10717544.2018.1477857","article-title":"Nanoparticle drug delivery systems: An excellent carrier for tumor peptide vaccines","volume":"25","author":"Wang","year":"2018","journal-title":"Drug Deliv."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1615\/CritRevTherDrugCarrierSyst.2013006955","article-title":"Peptide and protein delivery using new drug delivery systems","volume":"30","author":"Jain","year":"2013","journal-title":"Crit. Rev. Ther. Drug Carr. Syst."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jconrel.2012.02.021","article-title":"Delivery of drugs to cell membranes by encapsulation in PEG-PE micelles","volume":"160","author":"Wang","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"100970","DOI":"10.1016\/j.nantod.2020.100970","article-title":"Investigating the EPR effect of nanomedicines in human renal tumors via ex vivo perfusion strategy","volume":"35","author":"Ding","year":"2020","journal-title":"Nano Today"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","article-title":"Nanoparticle-liver interactions: Cellular uptake and hepatobiliary elimination","volume":"240","author":"Zhang","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"6655","DOI":"10.1021\/acsnano.5b01320","article-title":"Clearance Pathways and Tumor Targeting of Imaging Nanoparticles","volume":"9","author":"Yu","year":"2015","journal-title":"ACS Nano"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Sun, Z., Huang, J., Fishelson, Z., Wang, C., and Zhang, S. (2023). Cell-Penetrating Peptide-Based Delivery of Macromolecular Drugs: Development, Strategies, and Progress. Biomedicines, 11.","DOI":"10.3390\/biomedicines11071971"},{"key":"ref_61","first-page":"257","article-title":"The relevance of extramedullary hemopoiesis to the staging of chronic myeloid leukemia","volume":"57","author":"Baccarani","year":"1978","journal-title":"Boll. Ist. Sieroter. Milan."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jconrel.2013.11.020","article-title":"Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery","volume":"174","author":"Wang","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"10753","DOI":"10.1073\/pnas.1308345110","article-title":"Using shape effects to target antibody-coated nanoparticles to lung and brain endothelium","volume":"110","author":"Kolhar","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9986","DOI":"10.1021\/acsnano.5b03521","article-title":"The Interplay of Size and Surface Functionality on the Cellular Uptake of Sub-10 nm Gold Nanoparticles","volume":"9","author":"Jiang","year":"2015","journal-title":"ACS Nano"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.ccell.2020.03.006","article-title":"Response and Resistance to BCR-ABL1-Targeted Therapies","volume":"37","author":"Braun","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e2111451118","DOI":"10.1073\/pnas.2111451118","article-title":"Mutation in Abl kinase with altered drug-binding kinetics indicates a novel mechanism of imatinib resistance","volume":"118","author":"Lyczek","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1038\/sj.leu.2404924","article-title":"Deregulation of the Wilms\u2019 tumour gene 1 protein (WT1) by BCR\/ABL1 mediates resistance to imatinib in human leukaemia cells","volume":"21","author":"Svensson","year":"2007","journal-title":"Leukemia"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1024\/0040-5930\/a000385","article-title":"The spleen in hematologic malignancies","volume":"70","author":"Kienle","year":"2013","journal-title":"Ther. Umsch."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1038\/s41375-022-01682-2","article-title":"Splenic red pulp macrophages provide a niche for CML stem cells and induce therapy resistance","volume":"36","author":"Amrein","year":"2022","journal-title":"Leukemia"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/9\/2305\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:49:18Z","timestamp":1760129358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/9\/2305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,12]]},"references-count":69,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["pharmaceutics15092305"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15092305","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,12]]}}}